18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess xaliproden's potential capacity of slowing the
deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's
disease. The patients participating in this study will take orally once daily xaliproden or
placebo (inactive substance pill).